Faes Farma signs an agreement to acquire Laboratorios Edol, a leader in ophthalmology in Portugal

• Ophthalmology represents a key strategic opportunity for Faes Farma as it is a therapeutic area with expected double-digit growth.
• This milestone reinforces Faes Farma’s international growth strategy and consolidates its position in the Portuguese market.
• The integration of Edol will create sales synergies and enhances the group’s portfolio by adding complementary products.
• The operation is valued at 75 million euros.

Bilbao, 25 2025 – Faes Farma, S.A. has today signed a sale and purchase agreement, subject to suspensive conditions, to acquire 100% of Laboratorios Edol Productos Farmacêuticos, S.A., consolidating its expansion in the Portuguese market and in the ophthalmology area.

Founded in 1952, Laboratorios Edol is a leader in ophthalmology in Portugal, with annual sales in 2024 exceeding 30 million euros. It also has a modern production plant and a portfolio that strengthens Faes Farma’s portfolio by adding complementary products. The transaction, valued at 75 million euros (to be adjusted for net debt), will allow the Spanish group to double sales in Portugal and capitalise on commercial and operational synergies.

The acquisition of Laboratorios Edol represents a new strategic milestone in Faes Farma’s commitment to growth in international markets and strengthens its position in the Portuguese market , where the Group has been present for more than 80 years.

Laboratorios Edol has a portfolio of products and registrations that will also enable Faes Farma’s expansion and positioning in markets other than Portugal, taking advantage of Faes Farma’s existing commercial networks, both in Spain and in international markets.

Ophthalmology, a specialisation of Laboratorios Edol, is an area in which Faes Farma already has expertise in the development and launch of bilastin ophthalmic. In addition, represents a key strategic opportunity, with expected double-digit growth, driven not only by the ageing of the population resulting in pathologies such as glaucoma and dry eye, but also by the increase in symptoms caused by seasonal allergies and prolonged use of screens.

In short, this operation is part of Faes Farma’s international growth strategy, reinforcing its direct presence in Portugal and supporting the growth of the business through new therapeutic areas allowing the creation of synergies with the current R&D&I team.

The closing of the transaction is subject to the satisfactory completion of conditions precedent, including the submission of audited annual accounts for 2024 and the continuation of some of the existing commercial agreements with Laboratorios Edol.